Scientists can detect junk food consumption in blood and urine tests
Blood and urine tests have been found to detect the amount of ultraprocessed foods (UPFs) a person eats, according to new research.
Using machine learning, scientists at the National Institutes of Health (NIH) identified hundreds of metabolites (molecules produced during metabolism) that correlated with processed food intake.
The team developed a "biomarker score" that predicts ultraprocessed food intake based on metabolite measurements in blood and urine, according to Erikka Loftfield, Ph.D., M.P.H., of the National Cancer Institute in Maryland.
Premature Death Linked To Certain Type Of Food, Study Reveals
The researchers drew baseline data from 718 older adults who provided urine and blood samples and reported their dietary habits over a 12-month period, as detailed in a press release from NIH.
Next, they conducted a small clinical trial of 20 adults. For two weeks, the group ate a diet high in ultraprocessed foods, and for another two weeks they ate a diet with no UPFs.
Read On The Fox News App
"In our study, we found that hundreds of serum and urine metabolites were correlated with percentage energy from ultraprocessed food intake," Loftfield told Fox News Digital.
The findings were published in the journal PLOS Medicine.
The Worst Foods To Buy In The Supermarket And The Better Choices Instead
Large-scale studies investigating the health risks of ultraprocessed foods often rely on self-reported dietary questionnaires, which can be prone to errors, per the NIH.
The new blood and urine test helps to reduce human error by using objective biomarkers, a growing area of interest among researchers.
Loftfield added, "It was surprising to find that UPF-correlated metabolites are involved in numerous and diverse biological pathways, underscoring the complex impact of diet on the metabolome."
Ultraprocessed foods are defined as "ready-to-eat or ready-to-heat, industrially manufactured products, typically high in calories and low in essential nutrients," according to the NIH.
Chronic diseases, obesity and various forms of cancer have been linked to diets that are heavy in UPFs.
Despite promising results, the researchers emphasized that the new method will require further validation before broader use.
Since the current trial focused mainly on older adults, researchers say more research is needed across various age groups and diets.
"Metabolite scores should be evaluated and improved in populations with different diets and a wide range of UPF intake," Loftfield acknowledged.
Click Here To Sign Up For Our Health Newsletter
This method could potentially be used in future research to link the consumption of processed foods with chronic diseases, according to the researchers.
For more Health articles, visit www.foxnews.com/health
"For individuals concerned about ultraprocessed food intake, one practical recommendation is to use Nutrition Facts labels to avoid foods high in added sugars, saturated fat and sodium, as this can limit UPF intake and align with robust scientific research on diet and health," Loftfield suggested.Original article source: Scientists can detect junk food consumption in blood and urine tests
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Hampton Roads infant with rare genetic disorder in critical need of liver donor
PORTSMOUTH, Va. (WAVY) – Infant Rhett Powell will celebrate his first birthday Friday, but his parents are hoping to give him something far greater than a toy; they want him to have the gift of life. Rhett was diagnosed at just two months' old with a rare genetic disorder, Alagille Syndrome. Only about 1 in every 30,000 babies are born with the condition, according to the National Institutes of Health. His mother, Jenna, never imagined Rhett would be part of that statistic. At 10 months, doctors revealed his condition was compounded with liver disease and his parents also learned he would need a liver transplant. 'There's also a lot of risk with the transplant,' she says. 'And we know that the risk of a transplant outweighs keeping his liver the way it is. So, there's a mix of emotions: sadness, happiness, excitement, nervousness, all of the above. Alagille Syndrome is known to cause narrowed and malformed bile ducts in the liver, which is one of Rhett's toughest hurdles. His condition causes jaundice, issues with his heart and eyes, and itching so severe that he scratches until he bleeds. His blood is also highly acidic. Jenna says Rhett only weighs 16 lbs. and is on a feeding tube. His father was left with no choice but to quit his job as he can't crawl or move on his own. For the past two months, Jenna has been searching high and low for a liver donor who could be her baby boy's perfect match. 'His perfect match would be someone that has B or O blood type,' she says. 'Negative or positive, it doesn't matter. There would need to be aged around, 18 to 60. Nonsmoker, someone with no major organ diseases or preexisting conditions like diabetes or high blood pressure. No major abdominal surgeries; no illicit drug use. And someone that is willing to do that.' If you think you may be a match or know of someone who could be a match, you can contact Jenna Powell at (757) 556-5182. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
12 hours ago
- Yahoo
Curebound Challenges San Diego to Help Raise Vital Funding Amid Billions in Federal Grant Cuts that Threaten Cancer Research
Curebound launches all-new Curebound Cancer Challenge event and calls on individuals, corporations, and philanthropists to join together to support innovative cancer research as federal grants evaporate and scientists brace for more cuts next year SAN DIEGO, June 12, 2025--(BUSINESS WIRE)--Cancer research and the scientists conducting vital studies are facing an uncertain financial future. National Institutes of Health (NIH) slashed $1.81 billion in federal agency grants in 2025, according to an analysis published in JAMA1 (NBC News, 2025). Nearly 700 grants across 24 NIH institutes were affected, covering research on cancer, aging, diabetes and more. The federal administration has also proposed a 40% cut to NIH's 2026 budget2 (Reuters, 2025). Curebound, a philanthropic organization that invests in cancer research with the power to save lives, is committed to raising the funds needed to ensure the significant momentum in cancer research continues. Last month, Curebound's Concert for Cures: Elton John event at Petco Park raised $11.5 million, and Curebound continues the battle with an all-new Curebound Cancer Challenge on August 2 at UC San Diego. At Curebound Cancer Challenge (formerly Padres Pedal the Cause), Curebound invites San Diego's diverse communities to support important cancer research with a challenge to run, bike, walk, or spin and celebrate progress with an elevated fundraising experience. By increasing collaboration among philanthropists, corporations, those impacted by cancer, and the public, Curebound is focused on fostering community unity and a spirit of collaboration to accelerate cancer research into cures. The Curebound Cancer Challenge features three world-class 25 to 75-mile bike routes along San Diego's Torrey Pines coastline, a family friendly 5K, a new 10K run, 50-minute spin classes, entertainment, family activities and a team village where fundraising teams can gather and celebrate their fundraising efforts. This year, Challenge team signups are outpacing last year's with 130+ stepping forward to fundraise and support the most innovative cancer studies today. The Challenge is part of Curebound's ultimate goal of investing $100 million across early-stage cancer studies anchored in San Diego, with the potential to spread nationally through scientific collaborations. Every dollar donated will help fund pioneering cancer research among San Diego's top scientists and institutions including UC San Diego, Salk Institute, Sanford-Burnham Prebys, La Jolla Institute of Immunology and Scripps Research. Curebound CEO Anne Marbarger says, "Curebound has received a record number of research grant funding applications this year – due in large part to the current and potential federal agency cuts. With these cuts, many cancer studies will be reduced or eliminated, setting us back as we work to accelerate cures for cancer. The stakes are high. Now more than ever, we need to raise more and fund more. People with cancer can't afford to wait for federal budgets, court orders or maybes." Victor Manzanilla, Edward Jones Financial Advisor and Cancer Challenge Team Captain, says, "So many on our Edward Jones team have been affected by this disease. We are committed to doing what we can to lead in the fight against cancer – and that starts here at home in San Diego. We invite our fellow business leaders and their teams to join us on August 2 at UC San Diego and be part of this incredible effort to fund cutting-edge cancer research." Curebound Cancer Challenge is attracting corporate and institutional support from Edward Jones San Diego, UC San Diego, Janux Therapeutics, Vividion Therapeutics, JP Morgan, Lusardi Construction, Pfizer, Resmed, Thermo Fisher Scientific, BD, CBRE, Dexcom, Illumina, Genentech, Ranch & Coast, San Diego Self Storage, Koman Family Foundation, Maravai Life Sciences, WE O'Neil Construction, and Bernstein Private Wealth Management. For more information about how to get involved with the Curebound Cancer Challenge, contact Liz DeGeronimo at liz@ Register for Curebound Cancer Challenge. Early-bird incentives end June 15. About Curebound Curebound is a philanthropic organization that invests in cancer research with the power to save lives. Through collaborative grants, corporate partnerships, and strategic investments, Curebound's aim is to significantly accelerate better prevention, detection, and treatments for cancer. Headquartered in the major U.S. biotech hub of San Diego, amid 3,000+ life sciences companies, leading health systems, and world-class research institutions, Curebound partners with these organizations to forge interdisciplinary collaboration, foster knowledge sharing, and fund pioneering cancer research. So far, Curebound has funded $43+ million in cancer research, awarding 143 study grants for 23 types of pediatric and adult cancers with one vision: cures in our lifetime. Join us - View source version on Contacts Media Contact:Hilary McCarthy774.364.1440Hilary@ Sign in to access your portfolio
Business Wire
12 hours ago
- Business Wire
Curebound Challenges San Diego to Help Raise Vital Funding Amid Billions in Federal Grant Cuts that Threaten Cancer Research
SAN DIEGO--(BUSINESS WIRE)--Cancer research and the scientists conducting vital studies are facing an uncertain financial future. National Institutes of Health (NIH) slashed $1.81 billion in federal agency grants in 2025, according to an analysis published in JAMA 1 (NBC News, 2025). Nearly 700 grants across 24 NIH institutes were affected, covering research on cancer, aging, diabetes and more. The federal administration has also proposed a 40% cut to NIH's 2026 budget 2 (Reuters, 2025). 'The stakes are high. Now more than ever, we need to raise more and fund more. People with cancer can't afford to wait for federal budgets, court orders or maybes," says Curebound CEO Anne Marbarger. Curebound, a philanthropic organization that invests in cancer research with the power to save lives, is committed to raising the funds needed to ensure the significant momentum in cancer research continues. Last month, Curebound's Concert for Cures: Elton John event at Petco Park raised $11.5 million, and Curebound continues the battle with an all-new Curebound Cancer Challenge on August 2 at UC San Diego. At Curebound Cancer Challenge (formerly Padres Pedal the Cause), Curebound invites San Diego's diverse communities to support important cancer research with a challenge to run, bike, walk, or spin and celebrate progress with an elevated fundraising experience. By increasing collaboration among philanthropists, corporations, those impacted by cancer, and the public, Curebound is focused on fostering community unity and a spirit of collaboration to accelerate cancer research into cures. The Curebound Cancer Challenge features three world-class 25 to 75-mile bike routes along San Diego's Torrey Pines coastline, a family friendly 5K, a new 10K run, 50-minute spin classes, entertainment, family activities and a team village where fundraising teams can gather and celebrate their fundraising efforts. This year, Challenge team signups are outpacing last year's with 130+ stepping forward to fundraise and support the most innovative cancer studies today. The Challenge is part of Curebound's ultimate goal of investing $100 million across early-stage cancer studies anchored in San Diego, with the potential to spread nationally through scientific collaborations. Every dollar donated will help fund pioneering cancer research among San Diego's top scientists and institutions including UC San Diego, Salk Institute, Sanford-Burnham Prebys, La Jolla Institute of Immunology and Scripps Research. Curebound CEO Anne Marbarger says, 'Curebound has received a record number of research grant funding applications this year – due in large part to the current and potential federal agency cuts. With these cuts, many cancer studies will be reduced or eliminated, setting us back as we work to accelerate cures for cancer. The stakes are high. Now more than ever, we need to raise more and fund more. People with cancer can't afford to wait for federal budgets, court orders or maybes.' Victor Manzanilla, Edward Jones Financial Advisor and Cancer Challenge Team Captain, says, 'So many on our Edward Jones team have been affected by this disease. We are committed to doing what we can to lead in the fight against cancer – and that starts here at home in San Diego. We invite our fellow business leaders and their teams to join us on August 2 at UC San Diego and be part of this incredible effort to fund cutting-edge cancer research.' Curebound Cancer Challenge is attracting corporate and institutional support from Edward Jones San Diego, UC San Diego, Janux Therapeutics, Vividion Therapeutics, JP Morgan, Lusardi Construction, Pfizer, Resmed, Thermo Fisher Scientific, BD, CBRE, Dexcom, Illumina, Genentech, Ranch & Coast, San Diego Self Storage, Koman Family Foundation, Maravai Life Sciences, WE O'Neil Construction, and Bernstein Private Wealth Management. For more information about how to get involved with the Curebound Cancer Challenge, contact Liz DeGeronimo at liz@ Register for Curebound Cancer Challenge. Early-bird incentives end June 15. About Curebound Curebound is a philanthropic organization that invests in cancer research with the power to save lives. Through collaborative grants, corporate partnerships, and strategic investments, Curebound's aim is to significantly accelerate better prevention, detection, and treatments for cancer. Headquartered in the major U.S. biotech hub of San Diego, amid 3,000+ life sciences companies, leading health systems, and world-class research institutions, Curebound partners with these organizations to forge interdisciplinary collaboration, foster knowledge sharing, and fund pioneering cancer research. So far, Curebound has funded $43+ million in cancer research, awarding 143 study grants for 23 types of pediatric and adult cancers with one vision: cures in our lifetime. Join us -
